1EDELMAN M J,GANDARA D R,ROACH M3 R D,et al.Multimodality therapy in stage Ⅲ non-small cell lung cancer[J].Ann Thorac Surg,1996,61(5):1564-1572.
2ROSELL,GOMEZ C J,CAMPS C,et al.Pieresectional chemotherapy in stage ⅢA non-small-cell lung cancer:a 7-year assessment of a randomized controlled trial[J].Lung Cancer,1999,26(1):7-14.
3SPASOVA I,PETERA J,HYTYCH V.The role of neoadjuvant chemotherapy in marginally resectable or unresectable stage Ⅲ non-small-cell lung cancer[J].Neoplasma,2002,49(3):189-196.
4SHAROUNI S Y,KAL H B,BATTERMANN J J.Accele-rated regrowth of non-small-cell lung tumours after induction chemotherapy[J].Br J Cancer,2003,89(12):2184-2189.
5ALBERTI W,ANDERSON G,BARTOLUCCI A,et al.Chemotherapy in non-small cell lung cancer:a meta-analysis using updated data on individual patients from 52 randomised clinical trials[J].Br Med J,1995,311(7010):899-909.
6MANDZIUK S,DUDZISZ-SLEDZ M,KORSZEN-PILECKA I,et al.Expression of P21 and Bcl-2 proteins in paraffin-embedded preparations of non-small cell lung cancer in stage ⅢA after Etoposide and Cisplatin induced chemotherapy[J].Ann Univ Mariae Curie Sklodowska[Med],2003,58(1):149-153.
7HAN J Y,HONG E K,CHOI B G,et al.Death receptor-5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer[J].Med Oncol,2003,20(4):355-362.
9JUNKER K,MULLER K M,BOSSE U,et al.Apoptosis and tumor regression in locally advanced non-small cell lung cancer with neoadjuvant therapy[J].Pathologe,2003,24(3):214-219.
10JUNKER K.Therapy-induced morphological changes in lung cancer[J].Pathologe,2004,25(6):475-480.
二级参考文献30
1[1]von Knebel Doeberitz M, Lacroix J. Nucleic acid based techniques for the detection of rare cancer cells in clinical samples. Cancer Metastasis Rev,1999,18(1):43-64.
2[3]Ohgami A, Mitsudomi T, Sugio K, et al. Micrometastatic tumor cells in the bone marrow of patients with non-small cell lung cancer. Ann Thorac Surg,1997,64(2):363-367.
3[4]Mattioli S, D'Ovidio F, Tazzari P, et al. Iliac crest biopsy versus rib segment resection for the detection of bone marrow isolated tumor cells from lung and esophageal cancer. Eur J Cardiothorac Surg,2001,19(5):576-579.
4[5]Rosell R, Felip E, Maestre J, et al. The role of chemotherapy in early non-small-cell lung cancer management. Lung Cancer,2001,34(Suppl 3):S63-S74.
5[6]Braun S, Pantel K. Micrometastatic bone marrow involvement: detection and prognostic significance. Med Oncol,1999,16(3):154-165.
6[7]Maruyama R, Sugio K, Mitsudomi T, et al. Relationship between early recurrence and micrometastases in the lymph nodes of patients with stage Ⅰ non-small-cell lung cancer. J Thorac Cardiovasc Surg,1997,114(4):535-543.
7[8]Passlick B, Kubuschok B, Izbicki JR, et al. Isolated tumor cells in bone marrow predict reduced survival in node-negative non-small cell lung cancer. Ann Thorac Surg,1999,68(6):2053-2058.
8Rosell R, Gomez C J, Camps C, et al. Preresectional chemotherapy in stage Ⅲ A non-small-cell lung cancer:a 7-year assessment of a randomized controlled trial[J]. Lung Cancer, 1999, 26(1):7-14.
9Felp E, Rosell R. Neo-adjuvant chemotherapy in nonsmall cell lung cancer[J]. Carr Med Chem, 2002, 9(8):893-898.
10Hockenberg D, Nunez G, Milliman C, et al. Bcl-2 is inner mitochondrial protein that blocks programmed cell death[J]. Nature, 1990, 348-354.
